The interaction of antibodies, dengue virus (DENV), and monocytes can result in either immunity or enhanced virus infection. These opposing outcomes of dengue antibodies have hampered dengue vaccine development. Recent studies have shown that antibodies neutralize DENV by either preventing virus attachment to cellular receptors or inhibiting viral fusion intracellularly. However, whether the antibody blocks attachment or fusion, the resulting immune complexes are expected to be phagocytosed by Fc gamma receptor (FcγR)-bearing cells and cleared from circulation. This suggests that only antibodies that are able to block fusion intracellularly would be able to neutralize DENV upon FcγR-mediated uptake by monocytes whereas other antibodies would have resulted in enhancement of DENV replication. Using convalescent sera from dengue patients, we observed that neutralization of the homologous serotypes occurred despite FcγR-mediated uptake. However, FcγR-mediated uptake appeared to be inhibited when neutralized heterologous DENV serotypes were used instead. We demonstrate that this inhibition occurred through the formation of viral aggregates by antibodies in a concentration-dependent manner. Aggregation of viruses enabled antibodies to cross-link the inhibitory FcγRIIB, which is expressed at low levels but which inhibits FcγR-mediated phagocytosis and hence prevents antibody-dependent enhancement of DENV infection in monocytes. D engue is the most common mosquito-borne viral disease globally. The lack of an effective preventive measure, especially a licensed vaccine, has resulted in the global spread of this virus (1, 2). Although neutralizing antibodies can confer lifelong immunity against reinfection by one of the four dengue virus (DENV) serotypes, subneutralizing antibody levels or crossreactive antibodies appear to enhance the risk of severe dengue in subsequent infections (3-6). DENV bound with subneutralizing concentrations of antibody has been shown to result in increased virus uptake and replication in Fc gamma receptor (FcγR)-bearing cells such as monocytes/macrophages (4, 7). Thus, defining the determinants for virus neutralization will be important for the design of an effective dengue vaccine that protects against all four DENV serotypes while minimizing the risk of antibodydependent enhancement of DENV infection.Neutralization of flavivirus infection is a multiple-hit phenomenon. Recent stoichiometric studies have shown that both antibody affinity and epitope accessibility are important determinants for virus neutralization (8-10). Antibodies neutralize DENV by either preventing virus attachment to cellular receptors (11) or inhibiting viral fusion intracellularly (12). However, whether the antibody blocks attachment or fusion, the resulting immune complex is expected to be cleared from the circulation by professional phagocytes, especially the FcγR-bearing cells. This suggests that only antibodies that are able to block fusion intracellularly would be able to neutralize DENV upon FcγR-mediated uptake by ...